Alfuzosin Hydrochloride, introduced under the brand name 'Alfoo' is indicated for treatment of enlargement of prostate gland in ageing men known as Benign Prostatic Hyperplasia (BPH), a company release said.
The product was launched nationwide, and would further help the company consolidate its position in the urology segment which has over 10 products in the urology segment, the company informed the Bombay Stock Exchange.
The market size for the product as per April 2006 market data is valued at Rs 27 crore and the urology segment is estimated at Rs 65.08 crore.
Alfuzosin provides rapid relief from signs and symptoms of Benign Prostatic Hyperplasia (BPH) is a most common disorder among ageing men. The prevalence of BPH increases from 8 per cent in men between 31 and 40 years of age to 50 per cent in men between 51 and 60 years of age.
The shares of the company were trading at Rs 1,274.95, 0.07 per cent at the BSE
- » News Central
- » Popular News
- » Latest Health News
- » News Category A-Z (500+)
- » Health News and Press Release
- » News Archive
- » News Photo Gallery
- » Lifestyle and Wellness
- » Health Watch
- » Health In Focus
- » Celebrating Life
- » Breaking Health News
- » News From Other Resources
- » India Special
- » News Video Gallery
- » Medindia Exclusive - Interviews and In depth Reports